MRD testing in lymphoma grows fast, but varying assays and limited guidelines leave clinicians guessing; trials and standards clarify care.

In an interview, Vincent Ma, MD, explores the clinical utility of circulating tumor DNA dynamics to assess early outcomes in ...

Report finds hospitals price the same cancer drugs up to 2000x apart, worsening financial toxicity and intensifying demands for real transparency.

Sagar Lonial, MD, discusses the expanding potential uses of cereblon E3 ligase modulators (CELMoDs) in combination with T-cell redirection therapies in multiple myeloma. In a forward-looking interview ...

Real-time ctDNA MRD testing guides early chemo de-escalation in diffuse large B-cell lymphoma, aiming to cut toxicity without losing cure rates. In an interview with Targeted Oncology, Hua-Jay “Jeff” ...

Although immunotherapy progress in prostate cancer has been slow, emerging strategies like bispecific T-cell engagers (BiTEs) show promise in overcoming historical resistance. In a recent discussion, ...

The therapeutic landscape for cutaneous T-cell lymphoma (CTCL) is undergoing a significant shift with the emergence of denileukin diftitox (Lymphir), the first systemic treatment ...

Imaging suggests HCC, yet cirrhosis is uncertain—see why biopsy matters and how AFP, spread, and liver function shape treatment. For oncology clinicians, the Liver Imaging-Reporting and Data System ...

Leapman, MD, MHS, associate professor of urology at Yale University, addresses a critical and often overlooked limitation in the current landscape of prostate cancer biomarkers: while these tools have ...

In this interview, Sagar Lonial, MD, discussed the EXCALIBER-RRMM trial design and the potential role of iberdomide in the ...

DNA MRD monitoring offers new clues for stopping chemo safely in metastatic gastroesophageal cancer, linking molecular response to outcomes. In an interview with Targeted Oncology, Rutika Mehta, MD, ...

Interim phase 1b data showed 100% partial response rate in efficacy-evaluable CLL/SLL (4/4) after a median of at least three prior treatment lines. In heavily pretreated MZL (n=5), three complete ...